Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

摘要: The coexistence of EGFR and ALK-EML4 gene mutations represents a rare event (about 1%) in patients with non small cell lung cancer (NSCLC) the few cases described literature have all been treated by different methods. We present case 52-year-old woman adenocarcinoma whose tumor had this double genetic aberration. patient was immediately gefitinib because judged inoperable, but after two months she obtained an important clinical remission submitted to radical surgery. She is currently undergoing adjuvant treatment gefitinib. A review on aberration highlighted that further research needed define best therapeutic approach.